LTX-315 Completed Phase 1 Trials for Cancer With Transdermal Accessible Tumour Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01058616Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour